Seagen announces long-term results from tukysa® (tucatinib) pivotal trial in patients with her2-positive breast cancer during the virtual scientific program of the 2021 asco annual meeting

Bothell, wash.--(business wire)-- #asco2021--seagen announces long-term results from pivotal trial in patients with her2-positive breast cancer during the 2021 asco annual meeting

SGEN Ratings Summary

SGEN Quant Ranking